Monkeypox Vaccine And Treatment Market
Report ID: SQMIG35I2628
Report ID: SQMIG35I2628
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2628 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
90
|Figures:
71
Global Monkeypox Vaccine And Treatment Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 744.06 Million in 2025 to USD 1485.4 Million by 2033, growing at a CAGR of 9.02% during the forecast period (2026-2033).
The main factor influencing the monkeypox vaccine and treatment market growth is the repeat occurrence and worldwide spread of zoonotic diseases which have transitioned a once small biodefense industry into a present day necessity for public health. Included in this market includes vaccines, antivirals, diagnostic tools and their associated transport/ logistics for both preventative and clinical purposes. The overall goal of this market is to ultimately eliminate morbidity, preserve healthcare capacity and to contain the outbreak as quickly as possible to avoid societal disruptions. In past years, there has been low demand with any products being stored through a central stockpile. In recent years, however, with the continued outbreaks within West Africa along with the multi-country outbreak in 2022, the manufacturers received significant regulatory authorization for their products leading to an expansion in the number of manufacturers producing these products.
The purchasing of these products by national governments and international organizations also increased in part due to a focus on outbreak monitoring and the regulatory agility to utilize “ring vaccination” and issue emergency use authorizations as soon as outbreaks were detected. The result has been that by utilizing predictive purchasing methods that alleviate the commercial risk, manufacturers are expanding their ability to manufacture these products due to increased government purchasing. Consequently contract manufacturing, cold-chain logistics, and rapid point-of-care diagnostics become viable business lines while opportunities emerge for licensing, platform technology extension to other orthopoxviruses, and equitable distribution programs to ensure uptake in low-resource settings.
How is AI Accelerating Vaccine And Treatment Development In The Monkeypox Vaccine and Treatment Market?
By increasing discovery of candidate targets as well as developing more optimal vaccines, creating faster trial plans and faster virtual screenings for therapeutic molecules with AI technology, the development of monkeypox vaccine and treatment is being accelerated. Additionally, ML improves real-time surveillance (i.e. diagnostic image classification) and aids in determining response priority. The market is now focused on developing next-generation therapies and vaccines, rather than on emergency preparation of stockpiled products, due to the use of computational immunology and the growing availability of mRNA-based therapies being developed using in silico screening are being used by both research teams in academia and by industry manufacturing mRNA products to help shorten design cycles and allow for a focus on experimental activities.
Since then, another significant advancement has occurred related to a vaccine candidate for monkeypox (the GEO MVA vaccine) and related development program. Additionally, through AI-based antigen selection and trial optimization tools, GeoVax will be able to reduce timelines and more accurately forecast manufacturing and integrate data from public health organizations, thereby providing faster and more efficiently delivered public health response to the monkeypox outbreak.
Market snapshot - (2026-2033)
Global Market Size
USD 682.5 Million
Largest Segment
Vaccines
Fastest Growth
Vaccines
Growth Rate
9.02% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global monkeypox vaccine and treatment market is segmented by type, distribution and region. Based on type, the market is segmented into Vaccines and Treatments. Based on distribution, the market is segmented into Government Stockpiling, Hospital Pharmacies and Public Health Programs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per global monkeypox vaccine and treatment market outlook, the Government Stockpiling segment is flourishing, because centralized procurement and emergency preparedness strongly favor purchasing large quantities of prophylactic vaccines and therapeutics. This provides the manufacturers with an assured way to receive funding and have an ongoing source of demand for their products, which encourages them to invest in those products. The centralized buying power of the Government also reduces the likelihood that supply will be unstable, provides a strong incentive for manufacturers to commit to long-term production of products and assists in determining pricing and distribution characteristics for the monkeypox vaccine and treatment market by developing assured channels for the distribution of those products and encouraging investment in manufacturing scale and regulatory compliance.
As per global monkeypox vaccine and treatment market analysis, Hospital Pharmacies are emerging as fast developing distribution channels due to the growth in clinical demand for point-of-care administration of vaccines and integrated inventory management. Additionally, the increase in adoption by treatment centers and the increased efficiency of procurement by wholesalers has also resulted in increased demand for tailored cold chain solutions and opened up new sources of value added services and partnerships that are designed to increase the access to market and operational capacity for the monkeypox vaccine and treatment market.
As per global monkeypox vaccine and treatment market forecast, the vaccines segment continues to lead because prevention through immunization is still critical to control outbreaks and continues to receive significant funding from researchers to support product development and regulatory priority. There is also strong emphasis on protecting population-wide with a focus on the estimates of future vaccine demand as well as prioritizing clinical trials and developing strategic partnerships which help to reinforce supply commitments and pathways to commercialization in the Monkeypox Vaccine & Treatment Market. Therefore, vaccination will still be deployed in large numbers and will continue to be innovated upon.
The Treatments segment has been growing at the largest rate because of new therapeutic innovation, increased clinical guidelines, and increased need for an antiviral and supportive care treatment option. Within the Treatments segment there have been advances in formulation and expedited approvals which will allow for more patients to receive treatment, which will spur investments into models to treat patients in an outpatient environment as well as develop new commercial pathways that support ongoing prevention efforts and increase the overall available market.
To get detailed segments analysis, Request a Free Sample Report
As per global monkeypox vaccine and treatment market regional analysis, the North American region is taking the lead in the global marketplace, due to its established infrastructure for public health; extensive experience with the manufacturing of vaccines; and the collaborative regulatory mechanisms that help to accelerate the development and distribution of vaccine products. Collaborative investment by governmental agencies, universities, and biopharmaceutical companies supports ongoing investments in research programs, advanced networks for clinical trial execution, and supply chain resiliency. Well-developed frameworks for health care reimbursement and well-established immunization programs provide support for the adoption and distribution strategies of end-users. Companies benefit from having large areas of demand and access to contract manufacturers and specialized cold chain logistics when they are providing products to this market. The ULCC system established by all these companies have fully developed systems in place to support the monitoring of adverse events to ensure that their customers have confidence in them. Combining the depth of scientific expertise, the support of their regulatory environment by the federal and state governments, and the commercial maturity of the industry, North America is the premier regional hub for the development, manufacture, and utilization of monkeypox vaccines and therapeutics.
The U.S. monkeypox vaccine and treatment market is bolstered by established clinical networks, an active biopharma industry, and established distribution channels. Regulatory clarity, payer engagement, and public health agency collaboration provide support for market entry and adoption. Public health agencies provide support to immunization initiatives through coordinated outreach while private sector support provides R&D funding for new and innovative therapies for treatment of monkeypox. Established manufacturing and logistics capabilities ensure reliable supply and quality assurance. Collectively, these attributes for the U.S. monkeypox vaccine and treatment market provide a commercially viable environment that supports access to products, development of new products, and sustainability.
The Canadian monkeypox vaccine and treatment market is supported by an integrated public health sector, provinces working in unison, and cooperative consortia that are focused on research and access. Public health agencies are focused on equitable access to and procurement of vaccines and treatments to support the immunization initiatives. Domestic biotech activity and partnerships with international biopharma companies also enhance the accessibility of vaccines and treatments in Canada. Distribution of vaccines and treatments in Canada relies on urban-centered planning for delivery and regional distribution methods. The Canadian monkeypox vaccine and treatment market emphasizes alignment with regulatory standards and cooperation among multiple stakeholders, as well as providing an equitable, resilient supply chain, and limitation on time to commercial and clinical development.
As per global monkeypox vaccine and treatment market regional outlook, market expansion in Europe has been accelerated by the establishment and implementation of integrated health policy frameworks, collaborative initiatives between the different regulatory organizations across Europe, and the presence of many pharmaceutical research facilities. The existence of centralized procurement approaches and the establishment of coordinated public health plans has resulted in a more efficient process for distributing vaccines and therapeutics throughout these different markets. The existence of established manufacturing facilities and strong clinical research capabilities provide the ability to produce products regionally and to develop evidence based on local experience. Clinical collaborations across borders and the use of a shared surveillance system allow for the development of targeted responses and increased utilization. Regulatory pathways and active payer involvement help to facilitate the entry of products into these markets and provide a direct link between value assessment and public health priorities. The desire for investment dollars and the increasing presence of public/private partnerships provides additional momentum to the innovation pipeline while policymakers across Europe will continue to make policy decisions based on the principle of equitable access to patients.
The monkeypox vaccine and treatment market in Germany relies heavily on a well-established biotechnology infrastructure, a large network of clinical research organizations, and a coordinated public health system. The regulatory knowledge and expertise of integrated hospitals lend to a quick and robust clinical evaluation of potential therapies. The collaborative efforts between industry-based and research-based organizations are focused on generating evidence-based evaluations, as well as ensuring that products meet manufactured quality standards. The centralized purchasing of products and the efficient distribution logistics support the reliability of supply to consumers. The market also stresses the importance of scientific diligence in regulatory compliance, and investing in long-term capacity for research and development of vaccines and treatments for monkeypox.
In the UK, the monkeypox vaccine and treatment market utilizes an existing ecosystem of active clinical research, regulatory engagement with agility, and strong private sector investment in innovative technologies. The UK has a unified public health system that allows for quick access to products to be used in clinical research and the collection of evidence data for product adoption/support. There are collaborative networks that connect universities, biotechnology organizations, and clinical research sites to facilitate accelerated clinical trial and product refinement processes through shared resources and knowledge base. Logistics planning supports flexible product deployment, and the UK has a marketplace that promotes the introduction of innovative products, streamlined development of new products, and targeted strategies to address population health priorities.
The Monkeypox vaccine and treatment market in France is being driven by public health initiatives, increased research capacities, and changes in procurement practices. Health authorities are focusing on equity and the integration of immunisation programmes to help facilitate immunisation of all populations in France. Research institutions working with private companies are supporting the acceleration of clinical trials and product development through collaboration. The growth of manufacturing partnerships will also assist with supplying more products locally. These factors are contributing to the growing momentum in the marketplace through access policies, scientific advancement, and increasing commercial involvement across vaccines and treatments.
Investment is being made in order to improve regional research, increase manufacturing throughput, and facilitate regulatory engagement aimed at achieving international standards across the Asia Pacific region. Global biopharmaceutical companies can use cross-border collaborative projects and licensing agreements with local firms to transfer technology and create local production/processing capacity. Clinical trial capacity-building and improved systems for monitoring vaccine and therapeutic safety will enhance the region's capacity to effectively evaluate and utilize these products. Innovation ecosystems and supply chain diversity are supported through both public and private partnership initiatives, decreasing dependence on single-source supply. Government and private-sector stakeholders are striving to identify ways to improve access strategies and logistics in order to reach diverse segments of the population. Investment in regulatory harmonization, workforce development, and targeted funding for translational research is enhancing long-term capabilities and market competitiveness within the Asia Pacific region.
The Monkeypox vaccine and treatment market in Japan has grown by leveraging robust biotech research, a mature pharmaceutical manufacturing sector, and well-developed regulatory systems. Integrated surveillance and clinical assessment are supported by public health entities. Domestic companies can take advantage of technology transfer opportunities due to partnerships with overseas parties. Well-defined manufacturing quality systems allow for local production capacity. Policymakers have focused on equitable access and synchronised distribution to increase preparedness. Overall, the market showcases scientific excellence, regulatory accountability, and collaboration among all industry stakeholders.
The Monkeypox Vaccine and Treatment Market in South Korea is progressing through investments in biotech innovation, expanded clinical trial networks and industry programs. Regulatory agencies work with manufacturers to streamline evaluation while adhering to established standards. Through partnerships with global manufacturers, local production capacity and technology transfer have increased. Cold chain distribution reliability and access within regions are paramount in distribution planning. The market will consider both public health priorities and commercial motivations when developing ongoing vaccine and therapeutic products.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Public Health Awareness
The expansion of media and surveillance programs have drawn greater attention to the risks associated with monkeypox, leading to increased focus from policy makers and health systems on securing vaccines and therapies. Additionally, the sense of urgency that has developed with increased awareness and perception of risk will lead governments and international organizations to allocate resources for research, stockpiling and distribution planning, which will send signals of demand to manufacturers to scale up production and invest in supply chains. By working together, the public and private sectors can build partnerships to accelerate clinical development pathways and strengthen procurement commitments, thereby supporting market growth through increased demand and decreased commercial uncertainty for vaccine and treatment manufacturers.
Advances In Vaccine Technology
High Manufacturing Complexity
Certain vaccine types and specialty therapeutics must use highly skilled personnel and advanced manufacturing facilities capable of meeting stringent biosafety standards. Due to these high barriers, it will be hard for new producers to get into the market. The high barriers to entry create supply bottlenecks and delay timelines for expanding production scale, resulting in some manufacturers missing out on developing products. Capacity concentration with a small number of established producers increases risks associated with supply interruptions and reduces competition. All these manufacturing limitations create markets with less product available, more dependency on limited number of suppliers, fewer new suppliers entering the market, and less market access than if these constraints did not exist.
Regulatory Approval Complexity
Request Free Customization of this report to help us to meet your business objectives.
Competing today are established vaccine makers, antiviral companies, and agile biotech new entrants trying to get into supply contracts and emergency stockpiles. The primary market forces are the amount of product that can be manufactured and how much the government purchases. This has created specific marketplace strategies like Bavarian Nordic’s U.S. fill-finish agreement with Grand River Aseptic Manufacturing, SIGA’s regulatory efforts with tecovirimat, and BioNTech’s mRNA mpox clinical trial funded by the CEPI.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research
As per SkyQuest analysis, the global monkeypox vaccine and treatment sector is driven primarily by sustained government procurement tied to outbreak surveillance and regulatory agility, which creates predictable demand and incentivizes manufacturing scale-up. A second driver is rapid advances in vaccine technology and AI-enabled design that shorten development cycles and improve targeting. The market faces a key restraint in high manufacturing complexity that limits producer entry and creates supply bottlenecks. North America remains the dominating region due to integrated public health infrastructure and manufacturing capacity. While the vaccines segment is the dominating segment as preventive immunization continues to anchor outbreak control and investment priorities.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 682.5 Million |
| Market size value in 2033 | USD 1485.4 Million |
| Growth Rate | 9.02% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Monkeypox Vaccine And Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Monkeypox Vaccine And Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Monkeypox Vaccine And Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Monkeypox Vaccine And Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Monkeypox Vaccine And Treatment Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 744.06 Million in 2025 to USD 1485.4 Million by 2033, growing at a CAGR of 9.02% during the forecast period (2026-2033).
Competition centers on incumbent vaccine manufacturers, antiviral specialists and nimble biotech entrants vying for supply contracts and emergency stockpiles. Key market drivers include manufacturing capacity and government procurement, prompting concrete strategies such as Bavarian Nordic’s U.S. fill-finish partnership with Grand River Aseptic Manufacturing, SIGA’s regulatory push for tecovirimat, and BioNTech’s CEPI-backed mRNA mpox clinical program. 'Bavarian Nordic (JYNNEOS)', 'SIGA Technologies (TPOXX)', 'Chimerix (Brincidofovir)', 'Emergent BioSolutions', 'Pfizer Inc.', 'Johnson & Johnson', 'Merck & Co.', 'AstraZeneca', 'Takeda Pharmaceutical', 'Tonix Pharmaceuticals', 'Dynavax Technologies', 'Valneva SE', 'GeoVax Labs', 'iBio Inc.', 'Meridian Bioscience'
Expansion of surveillance programs and media coverage increase recognition of monkeypox risks, prompting policymakers and health systems to prioritize vaccination and therapeutic procurement. Increased perceived urgency motivates governments and international agencies to allocate resources toward research, stockpiling and distribution planning, creating demand signals that encourage manufacturers to scale production and invest in supply chains. This coordinated response fosters partnerships between public and private sectors, expedites clinical development pathways and strengthens procurement commitments, all of which support market growth by increasing demand and reducing commercial uncertainty for vaccine and treatment providers.
Decentralized Delivery Infrastructure: Stakeholders are increasingly prioritizing decentralized delivery models that bring vaccines and therapeutics to communities, leveraging community clinics and mobile units to improve accessibility. Emphasis on adaptable cold-chain solutions, workforce training and digital appointment systems supports an agile response to localized outbreaks. This shift enables faster uptake, strengthens trust through familiar care settings and enhances supply chain resilience by diversifying distribution nodes. The approach aligns with patient-centric strategies and encourages collaboration between national programs and local providers for preventive and treatment services.
Why does North America Dominate the Global Monkeypox Vaccine And Treatment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
